Aarti Drugs Ltd promoter group cuts shareholding by 2.27 million shares

What Aarti Drugs Ltd announced

On 27 June 2026, Aarti Drugs Ltd (BSE code 524348, NSE code AARTIDRUGS) filed a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing, submitted by Dilesh Roadlines Private Limited on behalf of the promoter group, details a series of market sales and a modest market purchase that together reduce the promoter‑group’s shareholding in the company.

The key numbers are:

• Dilesh Roadlines sold 125,998 shares, lowering its stake from 492,545 to 366,547 shares.
• Other promoters sold 1,769,641 shares, while a market purchase of 370,156 shares was recorded.
• The net change for the promoter group is a reduction of 2,265,795 shares.
• After the transactions, the promoter group holds 49,681,228 shares, about 55.7 % of the total equity capital of 91,270,000 shares (post‑buyback).

The filing confirms that the promoter group’s shareholding has fallen below the 1 % threshold that would otherwise trigger a mandatory offer under the Takeover Code.

Details of the share transactions

Dilesh Roadlines Private Limited

• Before transaction: 492,545 voting‑right shares (0.54 % of total equity).
• Transaction type: Market sale (buyback‑related sale).
• Shares sold: 125,998.
• After transaction: 366,547 voting‑right shares (0.40 % of total equity).

Other promoters and promoter group

The filing lists individual promoters and their holdings before and after the sale. The aggregate change for the non‑Dilesh promoters is a sale of 1,769,641 shares, offset partially by a market purchase of 370,156 shares. The net reduction for this cohort is 1,399,485 shares.

Net effect on promoter‑group holdings

*The figure of 50,714,166 represents the combined holdings of other promoters as disclosed in the annex.

The total equity share capital of Aarti Drugs Ltd, after a buyback of 665,000 shares in September 2024, stands at 91,270,000 shares. Consequently, the promoter group now controls ≈55.7 % of the company’s voting capital.

Regulatory context

Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 requires any person or group that acquires or disposes of shares resulting in a change of 1 % or more in the shareholding to disclose the change to the stock exchanges. The filing satisfies this requirement because the net reduction of 2.27 million shares translates to a ≈2.5 % decline in the promoter‑group’s stake relative to the total equity capital.

The disclosure does not indicate any new issuance of shares, rights issue, or preferential allotment. It merely records market‑based sales and a small purchase, all of which are off‑market transactions reported to the exchanges for transparency.

Why this matters for investors

• Shareholding transparency: The filing provides a clear picture of the promoter group’s current influence over Aarti Drugs Ltd. A 55.7 % holding still represents a controlling interest, but the reduction signals a modest dilution of promoter control.
• No dilution of equity: Because the transactions were sales rather than new issuances, existing shareholders are not subject to dilution of their proportional ownership.
• Regulatory compliance: The prompt filing under Regulation 29(2) demonstrates adherence to SEBI’s takeover and disclosure norms, reducing regulatory risk for the company.
• Potential impact on governance: While the promoter group remains the majority shareholder, the reduction may affect voting dynamics in future board or shareholder decisions, especially if the remaining shares are widely held.

Conclusion

Aarti Drugs Ltd’s promoter group, led by Dilesh Roadlines Private Limited, has reduced its shareholding by 2,265,795 shares, bringing the collective promoter stake to 49.68 million shares (≈55.7 % of total equity). The change was disclosed in compliance with SEBI Regulation 29(2) and does not involve any new share issuance. The filing completes the regulatory requirement; no further approvals or actions are pending under the takeover code.

Key facts at a glance